Sjogren's Syndrome
Welcome,         Profile    Billing    Logout  
 97 Companies   25 Products   25 Products   20 Mechanisms of Action   184 Trials   8247 News 


12345678910111213...144145»
  • ||||||||||  Review, Journal:  MEIBO (perfluorohexyloctane): a novel approach to treating dry eye disease. (Pubmed Central) -  Sep 6, 2024   
    The methods we used for this analysis are literature searches from PubMed, Medline and Google Scholar. This study aims to scour varying differentials of DED, its aetiology, general interventions, the latest refinements, and clinical efficacy, safety, and trials associated with Meibo (perfluorohexyloctane) in the management of DED.
  • ||||||||||  Journal:  Prognosis of Single Implant-Supported Prosthesis in Patients With Primary Sj (Pubmed Central) -  Sep 5, 2024   
    We provided an overview of the importance of a better stratification and characterization of the clinical heterogeneity of patients with inflammatory rheumatic diseases identifying this point as crucial in improving the management of these patients. Replacement of missing single teeth with dental implants was successful in patients with pSS 5?years after restoration.
  • ||||||||||  Journal:  Brain tumefactive vasculitis in primary Sj (Pubmed Central) -  Sep 5, 2024   
    Replacement of missing single teeth with dental implants was successful in patients with pSS 5?years after restoration. No abstract available
  • ||||||||||  Biomarker, Journal:  Meibomian gland dropout of upper eyelids as a novel biomarker for early diagnosis of primary Sj (Pubmed Central) -  Sep 4, 2024   
    MGD in the upper eyelids, especially in the temporal portion, is strongly associated with the histopathological outcome of labial salivary gland biopsy in pSS and is proposed as a highly predictive and noninvasive biomarker for the early diagnosis of pSS. ClinicalTrials.gov identifier: ChiCTR2000038911.
  • ||||||||||  Rituxan (rituximab) / Roche
    Journal:  Association of Sj (Pubmed Central) -  Sep 3, 2024   
    After a suspected or confirmed diagnosis of ITTP, plasma exchange and immunosuppressive therapy should be immediately administered. We suggest that rituximab could have additional therapeutic value for SS combined with ITTP and PRES.
  • ||||||||||  Review, Journal:  Prevalence, incidence, and mortality of Raynaud's phenomenon, Sj (Pubmed Central) -  Sep 3, 2024   
    There was a lack of high-quality systematic reviews for the prevalence and incidence of RP and Scleroderma. Therefore, further studies and systematic reviews with rigorous case definitions, assessing different ethnic groups are warranted in this area.
  • ||||||||||  Journal:  Unexpected Strikes: Sj (Pubmed Central) -  Sep 2, 2024   
    A repeat MRI showed new acute infarcts with dilatation of the ventricular system with periventricular ooze. The patient could not be revived and succumbed after one week of steroid therapy.
  • ||||||||||  Biomarker, Journal:  Identification and Validation of IFI44 as a Novel Biomarker for Primary Sj (Pubmed Central) -  Sep 2, 2024   
    Finally, the ceRNA regulatory network showed that hsa-miR-944, hsa-miR-9-5p, hsa-miR-126-5p, and hsa-miR-335-3p were significantly targeted IFI44, suggesting that IFI44 may serve as a dependable biomarker for pSS. In this study, we dug out IFI44 as a biomarker for pSS, systematically studied the potential regulatory mechanism of IFI44, and verified its reliability as a biomarker for pSS.
  • ||||||||||  Review, Journal:  Quintessence of currently approved and upcoming treatments for dry eye disease. (Pubmed Central) -  Sep 2, 2024   
    This study found that autoimmune diseases may act as protective factors against breast cancer risk. Currently, the US Food and Drug Administration (FDA)-approved medical treatments for treatment of DED include cyclosporine formulations (RESTASIS
  • ||||||||||  Journal:  Oral Mucosal Human Papillomavirus and Epstein-Bar Virus Rates in Patients with Dry Mouth and/or Sj (Pubmed Central) -  Sep 1, 2024   
    Orofacial mucosal HPV and/or EBV DNA rates did not differ statistically significantly in patients with xerostomia or hyposalivation or SS compared to healthy controls, therefore, it cannot prove the provocative role of these viruses in dry mouth and/or SS. Neither dry mouth nor SS were accompanied by statistically significantly more salivary gland alterations in HPV- and/or EBV-positive subjects; these alterations are frequent in the virus-negative cases too.
  • ||||||||||  Review, Journal:  Methylation of T and B Lymphocytes in Autoimmune Rheumatic Diseases. (Pubmed Central) -  Sep 1, 2024   
    Neither dry mouth nor SS were accompanied by statistically significantly more salivary gland alterations in HPV- and/or EBV-positive subjects; these alterations are frequent in the virus-negative cases too. This review summarizes the current state of research on the impact of DNA and RNA methylation on the development, differentiation, and function of T and B cells and examines the progress of these epigenetic modifications in studies of six specific ARDs: systemic lupus erythematosus, rheumatoid arthritis, Sj
  • ||||||||||  Review, Journal:  Auto-immuno-deficiency syndromes. (Pubmed Central) -  Sep 1, 2024   
    Thus, a common picture is emerging that both systemic and organ-directed autoimmune diseases may appropriately be described as auto-immuno-deficiency syndromes (AIdeSs), a concept that emphasizes and integrates existing knowledge on the role of immuno-deficiencies and chronic infections with development of overlapping disease syndromes with variable frequencies of autoantibodies and/or autoreactive T cells. This review integrates and exemplifies current knowledge on the interplay of genetically determined immuno-phenotypes and chronic infections in the development of AIdeSs.
  • ||||||||||  Journal:  Two Concomitant Rare Extraglandular Manifestations of Primary Sj (Pubmed Central) -  Sep 1, 2024   
    Autoimmune diseases can have overlapping clinical features and occasionally, manifest nonspecific symptoms leading to delay in diagnosis. It is therefore imperative to thoroughly evaluate any patient of pSS for early recognition of the diverse extraglandular features and initiate prompt treatment to improve outcome.
  • ||||||||||  Journal:  Transverse Myelitis in a 72-Year-Old Male Presenting With Upper Extremity Weakness. (Pubmed Central) -  Sep 1, 2024   
    Due to poor adherence to discharge instructions, the patient was readmitted after presenting to the emergency department with worsening symptoms. Physicians need to recognize and diagnose TM quickly, as some etiologies are treatable and can prevent further damage to the spinal cord.
  • ||||||||||  Review, Journal:  Mesenchymal stem cell therapy in veterinary ophthalmology: clinical evidence and prospects. (Pubmed Central) -  Sep 1, 2024   
    Future prospects in MSC therapy involve exploring scaffold and hydrogel-based approaches and cell-free therapies leveraging the bioactive molecules released by MSCs. Continued research and development efforts are essential to unlock the full therapeutic potential of MSCs and realize their transformative impact on ocular diseases in veterinary patients.
  • ||||||||||  hydroxychloroquine / Generic mfg., riluzole / Generic mfg.
    Journal:  Amyotrophic lateral sclerosis associated with Sj (Pubmed Central) -  Aug 31, 2024   
    It is recommended to include screening for SS in the standard assessment of ALS. Furthermore, research should focus on understanding the immune mechanisms involved in ALS, providing new insights for the diagnosis and treatment of ALS in conjunction with SS.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
    Journal:  A Case of TAFRO-like Symptoms in a Sj (Pubmed Central) -  Aug 31, 2024   
    Furthermore, research should focus on understanding the immune mechanisms involved in ALS, providing new insights for the diagnosis and treatment of ALS in conjunction with SS. The patient was diagnosed with TAFRO-like symptoms occurring with Sj
  • ||||||||||  Journal:  Coexistence of Sj (Pubmed Central) -  Aug 31, 2024   
    Rapid improvement in tubular injury markers and hypobicarbonemia followed potassium supplementation, suggesting that hypokalemia contributed to proximal tubular injury. This case underscores the diagnostic challenge posed by the simultaneous presence of TIN and hypokalemic nephropathy, potentially masking hypokalemic nephropathy in patients with hypokalemic dRTA secondary to SS-TIN.
  • ||||||||||  Preclinical, Journal, IO biomarker:  Altered characteristics of regulatory T cells in target tissues of Sj (Pubmed Central) -  Aug 31, 2024   
    and IL-17 that they produce warrants further investigations. In addition, enhancing the relatively weak immunosuppressive capacities of these Tregs may also serve as a viable strategy to alleviate the SS phenotype in the mouse models and potentially in patients.
  • ||||||||||  Journal:  Grp78 regulates NLRP3 inflammasome and participates in Sjogren's syndrome. (Pubmed Central) -  Aug 31, 2024   
    These findings lay the foundation for further investigation into the functionality of SGSCs influenced by ADF and shed light on the cellular and molecular mechanisms by which ADF exerts beneficial actions on salivary gland restoration in SS. FA induces the degradation of Grp78 protein, regulates the NF-?B signaling pathway in SS and inhibited NLRP3 inflammasome activation and reduced the release of inflammatory cytokines to alleviate SS.
  • ||||||||||  Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Journal:  The first report of leukocytoclastic vasculitis induced by once-weekly subcutaneous semaglutide. (Pubmed Central) -  Aug 31, 2024   
    Herein, we describe the first case of skin-limited LCV induced by once-weekly subcutaneous semaglutide in a 73-year-old man with T2DM, who experienced the complete resolution of the skin lesions shortly after the discontinuation of semaglutide therapy. Future prospective studies, adverse event reporting and post-marketing surveillance will certainly contribute to establishing if LCV represents a less rare than expected side effect of both oral and subcutaneous semaglutide formulations.
  • ||||||||||  Journal:  Novel autoantibodies help diagnose anti-SSA antibody negative Sj (Pubmed Central) -  Aug 27, 2024   
    The findings underscore the importance of recognizing elevated CeD antibodies in patients with SLE, pSS and SSc emphasizing the need for early detection and comprehensive care for gastrointestinal symptoms in these conditions. We present novel autoantibodies in SSA- SjD that have good predictive value for SSA- SjD and FS positivity.
  • ||||||||||  Journal, Causal relationship:  Causal relationship between multiple sclerosis and primary Sj (Pubmed Central) -  Aug 27, 2024   
    Serum BDNF level demonstrated greater predictive advantage for sleep disorder in pSS patients. No significant heterogeneity or horizontal pleiotropy was detected, supporting the reliability of the results.
  • ||||||||||  Biomarker, Retrospective data, Journal:  Salivary Gland Scintigraphy in Sj (Pubmed Central) -  Aug 26, 2024   
    Conclusions SGS is a significant diagnostic tool in the multiparametric evaluation of sicca syndrome, showing strong correlations with histological and immunological markers. Its integration into diagnostic criteria enhances the differentiation between SS and non-Sj
  • ||||||||||  Journal:  Research progress of Hippo pathway effector molecules in rheumatic immune system diseases. (Pubmed Central) -  Aug 26, 2024   
    Effector molecules,such as Yes-associated protein (YAP), transcriptional coactivator with PDZ-binding motif (TAZ), transcriptional enhanced associate domain transcriptional factor (TEAD), monopolar spindle-one binder (MOB1), large tumor suppressor (LATS), can stimulate fibroblast-like synovial cell migration and invasion in rheumatoid arthritis, regulate osteoarthritis disease progression, promote pathological new bone formation in ankylosing spondylitis, sustain submandibular gland development while delaying Sjogren's syndrome progression, mediate alpha-smooth muscle actin in systemic sclerosis, and refine the regulation of target genes associated with pulmonary fibrosis. This article provides an overview of the regulatory mechanisms involving Hippo signaling pathway-related effector molecules in the pathogenesis and progression of rheumatic immune system diseases, to serve as a reference for exploring novel therapeutic targets of rheumatic immune system diseases.